New study uncovers mechanisms of bacterial dormancy involving protein aggregation

Researchers revealed a mechanism involving protein aggregation that allows bacteria to enter a dormant state

Leuven, 28 January 2025 – Researchers at the VIB-KU Leuven Center for Microbiology and the VIB-KU Leuven Center for Brain & Disease Research revealed a mechanism involving protein aggregation that allows bacteria to enter a dormant state, a phenomenon that is associated with the persistence of infections and the challenge of antibiotic resistance. Their work appears in Nature Communications.

Sleeping bacteria

As antibiotic resistance continues to escalate globally, understanding how bacteria can evade treatment is more critical than ever. Some bacteria can enter dormant states, during which they are not susceptible to antibiotics. Dormant bacteria, including persister cells and viable but non-culturable cells (VBNCs), survive antibiotic exposure and can later ‘reactivate’, leading to recurrent infections. One of the bacteria that can pull off this trick is Escherichia coli, commonly associated with various infections in humans.

Led by Prof. Jan Michiels (VIB-KU Leuven) and Prof. Liselot Dewachter (UCLouvain), the researchers, alongside colleagues from the Switch lab (VIB-KU Leuven), explored the relationship between protein aggregation and bacterial dormancy.

“We found,” says Prof. Dewachter, “that when we subject bacteria to stress, proteins involved in their energy metabolism start to condensate, meaning that they start to clump together in gel-like droplets. Over time, these droplets solidify, which may protect the bacteria and help them survive. Interestingly, while protein aggregation has previously been associated with neurodegenerative diseases like Alzheimer’s, our findings reveal a surprising positive side to protein aggregation. Our work shows that protein aggregates are not necessarily detrimental, but can actually benefit cells by promoting their survival in stressful environments, such as during antibiotic treatment.”

Different states

The authors show that the two processes – bacterial dormancy and protein condensation – are tightly connected. By aggregating several proteins involved in metabolism, the condensation process effectively shuts down bacterial energy production.

Dr. Celien Bollen, first author of the study, explains, “We found that the timing of protein condensation and dormancy is closely linked across different strains of E. coli. This suggests that the process is conserved, potentially offering a therapeutic target for future treatments.”

Importantly, the scientists found that dormant E. coli cells can recover and regrow by dissolving these protein aggregates. The chaperone protein DnaK can literally pull proteins out of the condensates and reactivate bacterial metabolism.

“There are different states of dormancy,” explains Prof. Jan Michiels. “The bacteria first enter a persister state, where metabolism slows down and energy-related proteins start to form condensates, but they still show some activity, akin to a sleeping state. However, if the stress lasts, the protein droplets solidify and the bacteria transition into the VBNC state. In this state, metabolism drops even further, and it takes the bacteria longer to become active again, resembling more of a coma.”
“By disrupting the processes that lead to dormancy,” Bollen adds, “we may be able to improve the effectiveness of existing antibiotics and reduce the incidence of persistent infections. This is particularly relevant in the context of rising antibiotic resistance, which is a significant threat to public health.”
Celien Bollen and Jan Michiels

Publication

Composition and liquid-to-solid maturation of protein aggregates contribute to bacterial dormancy development and recovery. Bollen et al, Nature Communications, 2025.

Funding

This work was supported by FWO, KU Leuven, and VIB.


Gunnar De Winter

Gunnar De Winter

Science Communications Expert, VIB

 

 

Share

Latest stories

Website preview
Spectacular Breakthrough in Sepsis Research: Vitamin B1 Stops Deadly Lactate Production and Opens the Door to a New Treatment
Ghent, July 29, 2025 – Scientists in Ghent have achieved a major breakthrough in sepsis research. In a study on mice, the researchers demonstrate that vitamin B1 (thiamine pyrophosphate, TPP) restores mitochondrial energy metabolism, drastically reduces lactate production, and increases survival rates in sepsis. The study results were published in Cell Reports.
press.vib.be
Website preview
Scientists discover brain switch that controls freeze-or-flight survival instincts
Leuven, Belgium, 23 July 2025 – Researchers have identified a key neural switch that controls whether animals instinctively flee from a threat or freeze in place. By comparing two closely related deer-mouse species, they found that this switch is calibrated by evolution to match the animal's habitat. This neural circuit is hypersensitive in mice living in densely vegetated environments, causing instant escape, but less responsive in their open-field cousins, who are more likely to freeze. In doing so, the research team uncovered an important way in which evolution fine-tunes the brain for survival.
press.vib.be
Website preview
Groundbreaking Study Offers a Novel Approach to Enhance Neuromuscular Function in Patients with Duchenne Muscular Dystrophy
Findings published in The American Journal of Pathology identify GLUD1 enzyme as a potential therapeutic target for muscle restoration through metabolic reprogramming, addressing clinically unmet need for treatment beyond symptom relief
press.vib.be

About VIB

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be